Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Coya Therapeutics, Inc. ( (COYA) ) is now available.
On May 12, 2026, Coya Therapeutics reported first-quarter 2026 results and a corporate update, highlighting U.S. FDA Fast Track Designation granted on March 11, 2026 for its ALS candidate COYA 302 and FDA acceptance of an IND for COYA 302 in frontotemporal dementia. The company also cited new clinical and mechanistic data in ALS and FTD, protocol changes to broaden enrollment in its Phase 2 ALSTARS ALS trial, and a recent $11.1 million private placement, all supporting its strategy to advance COYA 302 and related platforms in neurodegenerative disease.
For the quarter ended March 31, 2026, Coya reported cash and equivalents of $50.7 million, flat collaboration revenue of $0.3 million, reduced R&D expenses of $4.1 million, higher G&A costs of $3.4 million linked largely to stock-based charges and a net loss of $7.2 million, similar to a year earlier. Management reiterated plans to fully enroll the ALSTARS Phase 2 trial and launch a Phase 2a FTD study for COYA 302 in the second half of 2026, positioning the company for key clinical and data milestones that could influence its standing in the ALS and FTD treatment landscape.
The most recent analyst rating on (COYA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
The score is held back primarily by persistent losses and ongoing cash burn, alongside weak technical trend signals (below major moving averages with negative MACD). Offsetting factors include a debt-free balance sheet with improved equity and positive corporate developments supporting liquidity and clinical progress.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a Houston-based clinical-stage biotechnology company focused on therapies targeting regulatory T cells to address systemic inflammation and neuroinflammation. Its pipeline includes Treg-enhancing biologics, Treg-derived exosomes and autologous Treg cell therapies aimed at neurodegenerative, metabolic and autoimmune diseases, with lead candidate COYA 302 being developed for ALS and other neurodegenerative conditions.
Average Trading Volume: 136,087
Technical Sentiment Signal: Sell
Current Market Cap: $96.41M
See more insights into COYA stock on TipRanks’ Stock Analysis page.